| Index | — | P/E | 45.00 | EPS (ttm) | 0.90 | Insider Own | 10.93% | Shs Outstand | 34.93M | Perf Week | -4.86% |
| Market Cap | 1.41B | Forward P/E | 25.52 | EPS next Y | 1.59 | Insider Trans | -0.47% | Shs Float | 33.16M | Perf Month | 3.21% |
| Enterprise Value | 1.86B | PEG | 3.05 | EPS next Q | 0.36 | Short Float | 3.46% | Perf Quarter | 4.90% | ||
| Income | 33.00M | P/S | 1.28 | EPS this Y | 21.84% | Short Ratio | 3.66 | Perf Half Y | 30.23% | ||
| Sales | 1.10B | P/B | 3.50 | EPS next Y | 13.25% | ROA | 3.12% | Short Interest | 1.15M | Perf YTD | 43.87% |
| Book/sh | 11.57 | P/C | 94.32 | EPS next 5Y | 14.74% | ROE | 9.51% | 52W High | 43.41 -6.70% | Perf Year | 64.57% |
| Cash/sh | 0.43 | P/FCF | 56.59 | EPS past 3/5Y | 56.30% 10.07% | ROIC | 5.03% | 52W Low | 22.26 81.94% | Perf 3Y | 276.04% |
| Dividend Est. | — | EV/EBITDA | 28.61 | Sales past 3/5Y | 26.08% 19.38% | Gross Margin | 14.79% | Volatility | 3.88% 3.16% | Perf 5Y | 65.31% |
| Dividend TTM | — | EV/Sales | 1.69 | EPS Y/Y TTM | 15.38% | Oper. Margin | 5.77% | ATR (14) | 1.38 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 1.20 | Sales Y/Y TTM | 37.63% | Profit Margin | 2.93% | RSI (14) | 47.38 | Recom | 2.14 |
| Dividend Gr. 3/5Y | — | Current Ratio | 1.20 | EPS Q/Q | 33.33% | SMA20 | -1.66% | Beta | 1.30 | Target Price | 44.50 |
| Payout | 0.00% | Debt/Eq | 1.14 | Sales Q/Q | 35.45% | SMA50 | 1.27% | Rel Volume | 0.96 | Prev Close | 41.66 |
| Employees | 9,700 | LT Debt/Eq | 1.13 | Earnings | Nov 04 | SMA200 | 14.11% | Avg Volume | 323.57K | Price | 40.50 |
| IPO Date | Oct 01, 2019 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 8.57% 3.21% | Net Debt/EBITDA | 6.85 | Volume | 311,123 | Change | -2.78% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-20-26 | Reiterated | RBC Capital | Outperform | $39 → $44 |
| Aug-11-26 | Reiterated | Wells Fargo | Overweight | $45 → $46 |
| Jul-14-26 | Reiterated | Truist Securities | Buy | $34 → $48 |
| Jul-13-26 | Reiterated | Wells Fargo | Overweight | $38 → $45 |
| May-08-26 | Reiterated | Oppenheimer | Outperform | $37 → $40 |
| Jan-07-26 | Reiterated | Wells Fargo | Overweight | $38 |
| Dec-16-25 | Reiterated | Jefferies | $30 → $40 | |
| Dec-02-25 | Upgrade | Truist Securities | Hold → Buy | |
| Nov-18-25 | Upgrade | Wells Fargo | Equal Weight → Overweight | |
| Nov-17-25 | Reiterated | RBC Capital | Outperform | $38 → $39 |
The Pennant Group, Inc. is a U.S.-based healthcare provider, delivering a diverse range of services through two core divisions: Home Health and Hospice Services, and Senior Living Services. The company's Home Health segment offers in-home clinical support, encompassing nursing, speech, occupational, and physical therapy, as well as medical social work and home health aide assistance. Its Hospice services focus on providing comprehensive clinical care, education, and counseling to meet the physical, spiritual, and psychosocial needs of terminally ill patients and their families. In its Senior Living division, Pennant provides residential accommodations, organized activities, meals, housekeeping, and aid with daily living tasks for seniors who are either independent or require some support. As of December 31, 2021, the company's extensive operational footprint included 88 home health and hospice agencies and 54 senior living communities, collectively featuring 4,127 senior living units. These facilities are located across Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The Pennant Group, Inc. was established in 2019 and maintains its corporate headquarters in Eagle, Idaho.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,101 | 948 | 695 | 545 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 939 | 825 | 601 | 478 | — | — | — | — | — | |
| Gross Profit | 162 | 122 | 94 | 67 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 95 | 71 | 50 | 37 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 4 | 0 | 6 | 5 | — | — | — | — | — | |
| Operating Income | 63 | 51 | 38 | 25 | — | — | — | — | — | |
| Interest Expense | 4 | 7 | 7 | 6 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -7 | 1 | 0 | 0 | — | — | — | — | — | |
| Net Income Before Taxes | 52 | 46 | 31 | 20 | — | — | — | — | — | |
| Income Taxes | 15 | 12 | 7 | 6 | — | — | — | — | — | |
| Consolidated Net Income | 33 | 30 | 23 | 13 | — | — | — | — | — | |
| Net Income From Continuing Operations | 38 | 34 | 24 | 14 | — | — | — | — | — | |
| Net Income | 33 | 30 | 23 | 13 | — | — | — | — | — | |
| EPS (Recurring) | 0.94 | 0.86 | 0.72 | 0.45 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.94 | 0.86 | 0.72 | 0.45 | — | — | — | — | — | |
| EPS (Diluted) | 0.90 | 0.84 | 0.71 | 0.44 | — | — | — | — | — | |
| EBITDA | 65 | 61 | 44 | 31 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 45.00 | 33.51 | 37.35 | 31.64 | — | — | — | — | — | |
| Price To Sales Ratio | 1.29 | 1.04 | 1.18 | 0.77 | — | — | — | — | — | |
| Gross Margin | 14.71 | 12.87 | 13.53 | 12.29 | — | — | — | — | — | |
| Operating Margin | 5.72 | 5.38 | 5.47 | 4.59 | — | — | — | — | — | |
| Net Margin | 3.00 | 3.16 | 3.31 | 2.39 | — | — | — | — | — | |
| Shares Outstanding | 35 | 35 | 31 | 30 | — | — | — | — | — | |
| Market Capitalization | 1,418 | 985 | 822 | 418 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Gochnour John J | Chief Operating Officer | Oct 23 '26 | Option Exercise | 6.10 | 5,948 | 36,283 | 151,412 | Oct 27 |
| Steik Jason Paul | Chief Clinical Officer | Aug 06 '26 | Sale | 38.52 | 1,394 | 53,700 | 15,106 | Aug 10 |
| Cheney Kirk Sterling | EVP, GC and Corp Secy | Aug 06 '26 | Sale | 38.52 | 1,393 | 53,661 | 18,401 | Aug 10 |
| Guerisoli Brent | Chief Executive Officer | Aug 06 '26 | Sale | 38.52 | 4,285 | 165,067 | 99,544 | Aug 10 |
| Guerisoli Brent | Chief Executive Officer | Jul 10 '26 | Option Exercise | 4.54 | 6,248 | 28,366 | 106,988 | Jul 14 |
| Guerisoli Brent | Chief Executive Officer | Jul 10 '26 | Sale | 41.56 | 3,159 | 131,304 | 103,829 | Jul 14 |
| Guerisoli Brent | Chief Executive Officer | Jul 07 '26 | Option Exercise | 4.54 | 6,249 | 28,370 | 103,905 | Jul 09 |
| Guerisoli Brent | Chief Executive Officer | Jul 07 '26 | Sale | 40.51 | 3,165 | 128,214 | 100,740 | Jul 09 |
| Guerisoli Brent | Chief Executive Officer | May 22 '26 | Option Exercise | 3.84 | 8,926 | 34,276 | 99,910 | May 27 |
| Guerisoli Brent | Chief Executive Officer | May 22 '26 | Sale | 35.08 | 4,508 | 158,140 | 95,447 | May 27 |
| Cheney Kirk Sterling | EVP, GC and Corp Secy | Nov 11 '25 | Option Exercise | 15.09 | 3,800 | 57,342 | 16,920 | Nov 13 |
| SMITH BARRY M | Director | Oct 09 '25 | Option Exercise | 11.35 | 10,000 | 113,500 | 94,899 | Oct 14 |
| Cheney Kirk Sterling | EVP, GC and Corp Secy | Jul 28 '25 | Sale | 23.34 | 880 | 20,539 | 13,120 | Aug 07 |
| Guerisoli Brent | Chief Executive Officer | Jul 28 '25 | Sale | 23.34 | 3,995 | 93,231 | 81,978 | Jul 31 |
| Stringfield JoAnne | Director | May 20 '25 | Option Exercise | 15.09 | 5,000 | 75,450 | 35,275 | May 23 |